We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 546

KC Animal Health Corridor claims 56 percent of total worldwide sales
  • Shook Hardy & Bacon LLP
  • USA
  • September 11 2014

An asset survey unveiled to animal health industry leaders during recent Kansas City (KC) Animal Health Corridor "homecoming" activities reportedly


Australian court finds human gene mutation to be patentable
  • Shook Hardy & Bacon LLP
  • Australia, USA
  • September 11 2014

A full panel of the Federal Court of Australia has upheld its earlier ruling that an isolated but naturally occurring nucleic acid, BRCA1, can be


Ranbaxy loses FDA approval for two generics
  • Shook Hardy & Bacon LLP
  • India, USA
  • November 13 2014

According to a statement that Ranbaxy Laboratories Ltd. provided to the Bombay Stock Exchange Website, the U.S. Food and Drug Administration (FDA


Report highlights growth in oncology R&D among midcap biotechs
  • Shook Hardy & Bacon LLP
  • USA
  • March 21 2013

Business intelligence company GlobalData has released a report on mid-cap biotech companies and concludes that their research and development (R&D


FDA argues to D.C. Circuit that stem cell treatment is a drug
  • Shook Hardy & Bacon LLP
  • USA
  • March 21 2013

Asserting that "FDA may lawfully regulate the creation of a new drug product even if it contains some of a patient's cells," the Food and Drug


House Subcommittee addresses policies blocking U.S. exports to India
  • Shook Hardy & Bacon LLP
  • India, USA
  • March 21 2013

The House Ways and Means Trade Subcommittee recently held a hearing on U.S.-India trade relations during which industry groups reportedly called on


CNS drug approvals take longer, are rejected more often
  • Shook Hardy & Bacon LLP
  • USA
  • November 13 2014

A new Tufts Center for the Study of Drug Development report reveals that drugs to treat central nervous system (CNS) disorders take longer to develop


Bio-Rad agrees to pay $55 million to resolve SEC bribery charges
  • Shook Hardy & Bacon LLP
  • USA
  • November 13 2014

A California-based clinical diagnostic and life science research company has reportedly agreed to pay $55 million to resolve U.S. Securities and


Ninth Circuit rules out state’s claims in class settlement with fetal-gender testing co
  • Shook Hardy & Bacon LLP
  • USA
  • November 13 2014

The Ninth Circuit Court of Appeals has enjoined California's effort to obtain restitution on behalf of individual citizens bound by the bargainedfor


College research program partners with diagnostics firm
  • Shook Hardy & Bacon LLP
  • USA
  • November 13 2014

The Baylor College of Medicine and diagnostics company Miraca Holdings have reportedly formed a joint ventureBaylor Miraca Genetics